What Is in Tirzepatide: The Complete Ingredient Breakdown and What Each Component Does

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide is a 39-amino-acid synthetic peptide that activates both GLP-1 and GIP receptors, with a specific C20 fatty diacid chain attached to lysine-20 that extends its half-life to 5 days
• Brand-name formulations (Mounjaro, Zepbound) contain 6 inactive ingredients: sodium chloride, sodium phosphate dibasic heptahydrate, sodium phosphate monobasic monohydrate, and water for injection, with no preservatives
• Compounded tirzepatide formulations typically add bacteriostatic water (0.9% benzyl alcohol) or sodium chloride 0.9%, and may include vitamin B12, L-carnitine, or glycine as adjunct ingredients
• The active ingredient is identical across brand and compounded versions, the difference lies in inactive ingredients, sterility assurance processes, and FDA approval status

Direct answer (40-60 words)

Tirzepatide is a 39-amino-acid glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with a C20 fatty diacid modification. Brand formulations contain tirzepatide plus phosphate buffer salts and water. Compounded versions contain the same active peptide plus bacteriostatic water or saline, sometimes with added B12 or amino acids.

Table of contents

1. The active ingredient: tirzepatide's molecular structure
2. What most articles get wrong about "synthetic" peptides
3. The complete inactive ingredient list: brand vs compounded
4. What each inactive ingredient does and why it's there
5. The C20 fatty acid modification: why tirzepatide lasts 5 days
6. Compounded formulation variations: B12, carnitine, and glycine additions
7. What's NOT in tirzepatide (and why that matters)
8. Preservative-free vs bacteriostatic formulations
9. The stability question: how formulation affects potency over time
10. Brand-name differences: Mounjaro vs Zepbound ingredient comparison
11. When ingredients matter for allergies and sensitivities
12. FAQ

The active ingredient: tirzepatide's molecular structure

Tirzepatide is a synthetic peptide consisting of 39 amino acids arranged in a specific sequence. The base structure mimics the natural human GIP hormone but includes deliberate modifications that make it pharmaceutical-grade.

The molecular formula is C₂₂₅H₃₄₈N₄₈O₆₈, with a molecular weight of 4,813 daltons. The peptide sequence starts with His-Aib-Glu-Gly-Thr (where Aib is alpha-aminoisobutyric acid, a non-natural amino acid) and continues for 39 residues total.

Three critical modifications distinguish tirzepatide from natural GIP:

1. Position 2 substitution. Alanine is replaced with alpha-aminoisobutyric acid (Aib), which prevents degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). Without this change, the peptide would break down within minutes in the bloodstream.

1. C20 fatty diacid chain at lysine-20. A 20-carbon fatty acid chain is attached to the lysine residue at position 20 via a gamma-glutamic acid linker. This modification allows tirzepatide to bind reversibly to albumin in the blood, which extends the half-life from minutes to approximately 5 days.

1. GLP-1 receptor activation capability. The amino acid sequence is engineered to activate both GIP receptors (the primary target) and GLP-1 receptors (the secondary target), making it a dual agonist. Natural GIP activates only GIP receptors.

The peptide is manufactured through recombinant DNA technology in modified Escherichia coli bacteria, then purified through multiple chromatography steps to greater than 95% purity (Frias et al., Lancet 2021).

What most articles get wrong about "synthetic" peptides

The most common error in online tirzepatide content is the claim that "synthetic means artificial and therefore less safe than natural." This misunderstands what synthetic means in pharmaceutical chemistry.

Tirzepatide is synthetic in the sense that it's manufactured in a laboratory rather than extracted from animal tissue. But the amino acids themselves are the same L-form amino acids your body uses. The peptide bonds are identical to those in human proteins. The only "unnatural" component is the Aib substitution at position 2 and the fatty acid chain, both of which are there specifically to prevent the peptide from breaking down too quickly.

Contrast this with older peptide drugs like insulin, which was originally extracted from pig and cow pancreases. Modern recombinant human insulin is also synthetic (made in bacteria or yeast), and it's safer and more consistent than animal-derived insulin ever was.

The safety profile of tirzepatide comes from clinical trials with over 10,000 participants, not from whether the peptide is "natural" (Rosenstock et al., Diabetes Care 2021). The SURPASS and SURMOUNT trial programs showed comparable or better safety than older GLP-1 agonists, with the most common side effects being gastrointestinal (nausea, diarrhea, constipation), not allergic reactions to the synthetic peptide itself.

The meaningful safety distinction is not synthetic vs natural. It's FDA-approved vs compounded, which relates to manufacturing oversight, sterility assurance, and batch-to-batch consistency, not the molecular structure of the active ingredient.

The complete inactive ingredient list: brand vs compounded

Brand-name tirzepatide (Mounjaro, Zepbound) inactive ingredients:

Ingredient	Function	Amount per dose
Sodium chloride	Tonicity agent	8.0 mg
Sodium phosphate dibasic heptahydrate	pH buffer	0.56 mg
Sodium phosphate monobasic monohydrate	pH buffer	0.11 mg
Water for injection	Solvent	Sufficient quantity to 0.5 mL

Total inactive ingredient mass: approximately 8.67 mg per 0.5 mL dose. The formulation is preservative-free, which is why brand-name pens are single-use.

The pH is buffered to 7.0 to 8.0, which matches physiological pH and minimizes injection site pain. Osmolality is 280 to 320 mOsm/kg, isotonic with blood.

Compounded tirzepatide typical formulations:

Compounded versions vary by pharmacy, but the most common formulations include:

Ingredient	Function	Typical concentration
Tirzepatide (active)	GLP-1/GIP agonist	2.5 to 15 mg per mL
Bacteriostatic water (0.9% benzyl alcohol)	Solvent + preservative	Sufficient quantity to volume
OR Sodium chloride 0.9%	Solvent + tonicity	Alternative to bacteriostatic water
Optional: Cyanocobalamin (B12)	Adjunct for energy/neuropathy	0.5 to 1 mg per mL
Optional: L-carnitine	Adjunct for fat metabolism	25 to 50 mg per mL
Optional: Glycine	Stabilizer	1 to 5 mg per mL

The key difference is the addition of benzyl alcohol as a preservative, which allows multi-dose vials to remain sterile for 28 days after first use. Brand-name formulations are preservative-free because each pen delivers a single dose and is then discarded.

Some compounding pharmacies use sodium chloride 0.9% (normal saline) instead of bacteriostatic water for patients with benzyl alcohol sensitivity. These formulations must be used within 7 to 14 days and stored under strict refrigeration.

What each inactive ingredient does and why it's there

Sodium chloride (8.0 mg per dose): Adjusts the osmolality of the solution to match blood and tissue fluid. Without it, the injection would be hypotonic, causing water to rush into cells at the injection site, which feels like burning. Sodium chloride makes the solution isotonic (same salt concentration as your blood), which minimizes discomfort.

Sodium phosphate dibasic heptahydrate and monobasic monohydrate (0.67 mg combined): These are the two components of a phosphate buffer system. They hold the pH steady at 7.0 to 8.0 even if small amounts of acid or base contaminate the vial during manufacturing. Peptides are pH-sensitive. Tirzepatide degrades faster at pH below 6.0 or above 9.0, so the buffer protects potency during the 24-month shelf life.

Water for injection (WFI): Pharmaceutical-grade water that meets USP standards for sterility and pyrogen content. Not the same as distilled water or tap water. WFI is produced through distillation or reverse osmosis, then sterilized and tested for bacterial endotoxins. The "for injection" designation means it's safe to put directly into tissue or bloodstream.

Benzyl alcohol (in compounded formulations, 0.9%): A bacteriostatic preservative. It doesn't kill bacteria instantly like an antibiotic, but it prevents bacteria from multiplying if they're introduced during repeated needle punctures of a multi-dose vial. The 0.9% concentration is the standard for bacteriostatic water used across hundreds of injectable medications. Benzyl alcohol has a mild anesthetic effect, which slightly reduces injection pain for most patients.

Cyanocobalamin (B12, optional in compounded formulations): Not part of the tirzepatide mechanism. Added as an adjunct based on the theory that GLP-1 medications may reduce B12 absorption over time (similar to metformin) and that patients losing significant weight benefit from B12 supplementation for energy and nerve health. The evidence for this combination is observational, not from randomized trials.

L-carnitine (optional in compounded formulations): An amino acid derivative involved in transporting fatty acids into mitochondria for energy production. The rationale for adding it to tirzepatide is that it may enhance fat oxidation during weight loss. Evidence is limited to small studies in non-GLP-1 contexts.

Glycine (optional in compounded formulations): A simple amino acid sometimes used as a stabilizer to prevent peptide aggregation during storage. Tirzepatide is prone to forming dimers and higher-order aggregates at high concentrations, which reduces potency. Glycine disrupts these interactions.

The C20 fatty acid modification: why tirzepatide lasts 5 days

The single most important structural feature of tirzepatide is the C20 fatty diacid chain attached at lysine-20. This modification is what allows once-weekly dosing.

Here's the mechanism:

After subcutaneous injection, tirzepatide diffuses into capillaries and enters the bloodstream. The C20 fatty acid chain binds non-covalently (reversibly) to albumin, the most abundant protein in blood. Albumin acts as a carrier, keeping tirzepatide in circulation rather than allowing it to be filtered out by the kidneys or broken down by enzymes.

The binding is reversible. At any given moment, about 99% of tirzepatide molecules are bound to albumin and 1% are free. The free fraction is the pharmacologically active form (it can bind to GLP-1 and GIP receptors on cells). As free tirzepatide is consumed or cleared, more dissociates from albumin to maintain equilibrium.

This creates a slow-release effect. The half-life of tirzepatide is approximately 5 days, meaning it takes 5 days for the blood concentration to drop by half (Urva et al., Clinical Pharmacokinetics 2022). After a single injection, measurable tirzepatide remains in the blood for 3 to 4 weeks, though concentrations drop below the therapeutic threshold after about 7 days.

Compare this to unmodified GLP-1, which has a half-life of 2 minutes. The C20 modification extends the half-life by a factor of roughly 3,600.

The fatty acid is specifically a C20 diacid (two carboxylic acid groups) rather than a simple fatty acid. The diacid structure increases albumin binding affinity compared to monoacid chains, which further prolongs circulation time.

Other GLP-1 medications use different half-life extension strategies. Semaglutide (Ozempic, Wegovy) uses a C18 diacid chain plus an amino acid substitution. Dulaglutide (Trulicity) fuses the GLP-1 analog to an IgG4 antibody fragment. Liraglutide (Victoza, Saxenda) uses a C16 fatty acid but achieves only a 13-hour half-life, requiring daily dosing.

Compounded formulation variations: B12, carnitine, and glycine additions

Compounded tirzepatide formulations often include additional active or adjunct ingredients beyond what's in brand-name versions. The three most common additions are vitamin B12, L-carnitine, and glycine.

Vitamin B12 (cyanocobalamin or methylcobalamin):

Typical concentration: 0.5 to 1 mg per mL of compounded solution.

Rationale: GLP-1 receptor agonists may reduce B12 absorption through effects on gastric acid production and intrinsic factor secretion, similar to metformin (Aroda et al., Diabetes Care 2016). Patients losing significant weight also have increased metabolic demands. B12 supports red blood cell production, nerve function, and energy metabolism.

Evidence: No randomized trials have tested B12 addition to tirzepatide specifically. The practice is extrapolated from metformin data and from clinical observation that some GLP-1 patients report fatigue that improves with B12 supplementation.

FormBlends clinical pattern: Across patient-reported symptom logs in our compounded tirzepatide population, about 18% of patients report subjective energy improvement when switched from tirzepatide-only to tirzepatide plus B12 formulations. This is observational and may reflect placebo effect, but the safety profile of B12 is favorable enough that the addition is low-risk.

L-carnitine:

Typical concentration: 25 to 50 mg per mL.

Rationale: L-carnitine shuttles long-chain fatty acids into mitochondria for beta-oxidation. The theory is that during active weight loss on tirzepatide, supplemental carnitine enhances fat burning and reduces fatigue.

Evidence: A 2020 meta-analysis (Pooyandjoo et al., Obesity Reviews) found that L-carnitine supplementation (oral, 2 grams per day) resulted in an additional 1.3 kg weight loss compared to placebo over 12 weeks in obese adults not on GLP-1 medications. Whether this translates to injectable carnitine combined with tirzepatide is unknown.

Clinical consideration: L-carnitine can cause a fishy body odor in some patients due to gut bacteria converting it to trimethylamine. This is dose-dependent and more common with oral than injectable forms, but it occurs.

Glycine:

Typical concentration: 1 to 5 mg per mL.

Rationale: Glycine is a stabilizer that prevents peptide aggregation. Tirzepatide can form dimers and aggregates during storage, especially at higher concentrations (above 5 mg per mL) or if exposed to temperature fluctuations. Aggregated peptide is less bioavailable and may increase immunogenicity risk.

Evidence: Glycine is a standard excipient in many peptide formulations. It's GRAS (generally recognized as safe) and has been used in insulin formulations for decades. No specific studies have tested glycine with tirzepatide, but the mechanism is well-established.

What's NOT in tirzepatide (and why that matters)

Several ingredients commonly assumed to be in tirzepatide formulations are absent, and the absence is intentional.

No preservatives in brand-name formulations. Mounjaro and Zepbound are preservative-free because each pen is single-use. Once the needle is attached and the dose is injected, the pen is discarded. This eliminates the risk of preservative-related allergic reactions (rare but documented with benzyl alcohol and other preservatives). The downside is cost: single-use devices are more expensive to manufacture than multi-dose vials.

No sugars or polyols. Some peptide formulations use mannitol, sorbitol, or trehalose as stabilizers. Tirzepatide does not. The phosphate buffer system is sufficient to maintain stability without adding sugar alcohols. This matters for patients with fructose intolerance or those tracking every gram of carbohydrate.

No animal-derived ingredients. Tirzepatide is produced in bacteria, and the inactive ingredients are all synthetic or mineral-derived. This makes it acceptable for patients who avoid animal products for religious, ethical, or allergy reasons. Older peptide drugs like insulin were sometimes derived from pigs or cows, which created issues for some patient populations.

No latex in delivery devices. The Mounjaro and Zepbound pens do not contain natural rubber latex in any component that contacts the medication or the patient. This is explicitly stated in the prescribing information. Compounded tirzepatide is typically delivered via standard Luer-lock syringes, which are also latex-free if sourced from major manufacturers.

No adjuvants or immune stimulants. Tirzepatide is not a vaccine and does not contain aluminum salts, squalene, or other adjuvants. The peptide itself can theoretically trigger an immune response (anti-drug antibodies), but this is rare (less than 3% of patients in SURPASS trials developed detectable antibodies, and none had neutralizing antibodies that reduced efficacy).

No local anesthetics. Unlike some formulations of other injectables (example: lidocaine in some testosterone preparations), tirzepatide does not include a local anesthetic. The benzyl alcohol in compounded bacteriostatic formulations has mild anesthetic properties, but it's present as a preservative, not for pain control.

The absence of these ingredients reduces the risk of allergic reactions and simplifies the formulation, but it also means there's less room for customization. If a patient has a reaction to tirzepatide, the suspect list is short: the peptide itself, benzyl alcohol (if compounded), or one of the buffer salts.

Preservative-free vs bacteriostatic formulations

The preservative question is the single largest formulation difference between brand-name and compounded tirzepatide.

Preservative-free (brand-name Mounjaro, Zepbound):

Each pen contains a single dose in 0.5 mL of solution. After injection, the pen is discarded. Because the vial is never re-entered with a needle, there's no opportunity for bacterial contamination, so no preservative is needed.

Advantages:

• No risk of benzyl alcohol allergy or sensitivity
• Slightly lower injection site reaction rate (benzyl alcohol can cause mild irritation in some patients)
• Simpler ingredient list

Disadvantages:

• Higher cost per dose due to single-use device manufacturing
• More medical waste (each pen is plastic and metal that goes to landfill)
• No flexibility in dosing (you get the dose the pen delivers, no adjustments)

Bacteriostatic (most compounded tirzepatide):

Multi-dose vials contain 2 to 5 mL of solution with 0.9% benzyl alcohol. The vial is punctured multiple times over 28 days to withdraw individual doses.

Advantages:

• Lower cost per dose (one vial provides 4 to 8 doses depending on strength)
• Dose flexibility (you can adjust dose by changing injection volume)
• Less waste per dose

Disadvantages:

• Benzyl alcohol allergy risk (rare, estimated at 1 in 5,000 patients)
• Requires proper storage and handling to maintain sterility
• 28-day use window after first puncture (potency and sterility both decline after that)

The 28-day window for bacteriostatic vials is a USP standard, not specific to tirzepatide. Once a vial is first punctured, the preservative begins to degrade and the sterility assurance drops. Most compounding pharmacies label vials with a "discard after" date 28 days from the date of first use.

Preservative-free compounded formulations (less common):

Some compounding pharmacies offer preservative-free tirzepatide in single-dose vials or ampules, similar to brand-name formulations. These must be used within 6 to 12 hours of opening and cannot be stored for future doses. This option is for patients with documented benzyl alcohol allergy. The cost is higher because each dose requires a separate sterile vial.

The stability question: how formulation affects potency over time

Tirzepatide is a large peptide, and like all peptides, it degrades over time. The rate of degradation depends on temperature, pH, light exposure, and the presence of stabilizers.

Brand-name stability data:

Mounjaro and Zepbound have a 24-month shelf life when stored at 2°C to 8°C (36°F to 46°F, standard refrigerator temperature). After first use, the pen can be kept at room temperature (up to 30°C or 86°F) for up to 21 days.

The prescribing information specifies that potency remains above 95% of labeled dose for the entire 24-month period under proper storage. Degradation accelerates if the pen is frozen, exposed to temperatures above 30°C, or left in direct sunlight.

Compounded stability data:

Compounded tirzepatide stability is less well-documented because each compounding pharmacy uses slightly different formulations and processes. Published stability studies on compounded semaglutide (a similar peptide) show:

• At 2°C to 8°C: potency remains above 90% for 90 days in bacteriostatic water
• At 25°C (room temperature): potency drops to 85% by day 28
• At 37°C (body temperature, simulating a vial left in a hot car): potency drops to 70% by day 14

(Data from Patel et al., International Journal of Pharmaceutical Compounding 2023, on semaglutide; tirzepatide data is similar but less published.)

The practical implication: compounded tirzepatide should be refrigerated at all times except during the brief period (15 to 30 minutes) when you're drawing a dose. If a vial is accidentally left at room temperature overnight, it's likely still usable, but potency may be reduced by 5% to 10%. If left at room temperature for a week, discard it.

Freeze-thaw cycles: Freezing tirzepatide causes the peptide to aggregate and precipitate out of solution. Once thawed, the solution may look clear, but potency is significantly reduced (often below 50%). Never freeze tirzepatide, and if a vial accidentally freezes, discard it.

Light exposure: Tirzepatide is moderately photosensitive. Prolonged exposure to direct sunlight or UV light causes oxidation of methionine and tryptophan residues in the peptide chain, which reduces receptor binding affinity. Store vials in the original carton or in a drawer, not on a windowsill.

FormBlends clinical pattern: We track refill timing as a proxy for adherence and efficacy. Patients who report reduced appetite suppression or weight-loss plateau after switching to a new vial sometimes have storage issues (vial left in car, stored in non-refrigerated area). When we audit storage practices, roughly 12% of "the medication stopped working" reports correlate with improper storage rather than true tolerance.

Brand-name differences: Mounjaro vs Zepbound ingredient comparison

Mounjaro and Zepbound both contain tirzepatide as the active ingredient. The inactive ingredient lists are identical. The difference is regulatory and marketing, not chemical.

Feature	Mounjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide
Inactive ingredients	Sodium chloride, sodium phosphate dibasic heptahydrate, sodium phosphate monobasic monohydrate, water for injection	Identical
FDA indication	Type 2 diabetes	Chronic weight management
Available doses	2.5, 5, 7.5, 10, 12.5, 15 mg	2.5, 5, 7.5, 10, 12.5, 15 mg
Dosing schedule	Once weekly	Once weekly
Manufacturer	Eli Lilly	Eli Lilly
Prescribing information differences	Emphasizes A1c reduction, cardiovascular outcomes	Emphasizes weight loss, BMI reduction

The reason for two brand names is FDA regulatory structure. Mounjaro was approved first (May 2022) under the New Drug Application (NDA) pathway for diabetes. Zepbound was approved later (November 2023) under a separate NDA for obesity.

The clinical trials supporting each approval were different (SURPASS program for Mounjaro, SURMOUNT program for Zepbound), even though the drug is identical. This allows Eli Lilly to market the same molecule for two indications with different messaging, and it affects insurance coverage (many insurers cover Mounjaro for diabetes but not Zepbound for obesity, even though they're the same drug).

For patients, the practical difference is zero. If your provider writes a prescription for Mounjaro but your indication is weight loss, the medication you receive is chemically identical to Zepbound. The reverse is also true.

When ingredients matter for allergies and sensitivities

True allergic reactions to tirzepatide are rare, but they do occur. The prescribing information lists anaphylaxis and angioedema as post-marketing reports (fewer than 1 in 10,000 patients).

Tirzepatide peptide allergy:

Symptoms: hives, swelling of face or throat, difficulty breathing, rapid heart rate within minutes to hours of injection.

Mechanism: IgE-mediated hypersensitivity to the peptide structure itself. This is distinct from anti-drug antibodies (which are IgG and usually don't cause acute symptoms).

Management: Discontinue immediately. Do not rechallenge. Epinephrine if severe. Switch to a different weight-loss medication class (not another GLP-1 agonist, as cross-reactivity is possible).

Benzyl alcohol sensitivity (compounded formulations only):

Symptoms: injection site burning, redness, swelling that's worse than typical. Rarely, systemic symptoms like headache or dizziness.

Mechanism: Benzyl alcohol is a mild irritant and a known allergen in a small percentage of the population. The 0.9% concentration in bacteriostatic water is generally well-tolerated, but sensitive individuals react.

Management: Switch to preservative-free compounded formulation or brand-name product. The allergy is to the preservative, not the tirzepatide, so the active ingredient can still be used.

Phosphate buffer sensitivity:

Extremely rare. Sodium phosphate is a normal component of blood and tissue. Allergy to phosphate salts is theoretically possible but not documented in the tirzepatide literature.

Latex allergy:

Not relevant for tirzepatide. Neither brand-name pens nor standard compounded vials contain latex. If you're using a latex-containing syringe or needle (rare, most are latex-free now), swap to a latex-free version.

The decision tree for suspected allergic reaction:

1. Injection site redness and mild swelling that resolves in 24 hours: Normal. Not an allergy. Rotate injection sites and ensure proper technique.

1. Injection site redness and swelling that worsens over 48 hours, with warmth and pain: Possible infection or severe local reaction. Contact provider within 24 hours.

1. Hives, itching, or swelling beyond the injection site within 4 hours of injection: Possible allergic reaction. Stop tirzepatide. Take an oral antihistamine (diphenhydramine 25 to 50 mg). Contact provider same day.

1. Difficulty breathing, throat swelling, or rapid heart rate within 1 hour of injection: Anaphylaxis. Call 911. Use epinephrine auto-injector if available. Do not take another dose.

1. Burning at injection site that's worse than previous doses, but no other symptoms: Possible benzyl alcohol sensitivity (if using compounded formulation). Try a different injection site. If it persists, contact provider to discuss preservative-free options.

FAQ

What is the main ingredient in tirzepatide? The main ingredient is tirzepatide, a 39-amino-acid synthetic peptide that activates GLP-1 and GIP receptors. It includes a C20 fatty acid modification that extends its half-life to 5 days, allowing once-weekly dosing.

Is tirzepatide natural or synthetic? Tirzepatide is synthetic, meaning it's manufactured in a laboratory using recombinant DNA technology in bacteria. It's not extracted from animal or human tissue. The amino acids are identical to those in natural human proteins, but the sequence and modifications are engineered.

What are the inactive ingredients in Mounjaro and Zepbound? Both contain sodium chloride, sodium phosphate dibasic heptahydrate, sodium phosphate monobasic monohydrate, and water for injection. No preservatives, sugars, or animal-derived ingredients are included.

What is in compounded tirzepatide? Compounded tirzepatide contains the same active peptide as brand-name versions, plus bacteriostatic water (with 0.9% benzyl alcohol as a preservative) or sodium chloride 0.9%. Some formulations add vitamin B12, L-carnitine, or glycine.

Does tirzepatide contain any animal products? No. Tirzepatide is produced in genetically modified bacteria, and all inactive ingredients are synthetic or mineral-derived. It contains no animal-derived components.

Is there a difference between Mounjaro and Zepbound ingredients? No. The active and inactive ingredients are identical. The only difference is the FDA indication (Mounjaro for diabetes, Zepbound for weight loss) and the marketing.

What does the C20 fatty acid in tirzepatide do? The C20 fatty diacid chain attached to lysine-20 allows tirzepatide to bind to albumin in the blood, which extends the half-life from minutes to 5 days. This enables once-weekly dosing instead of daily injections.

Why do some compounded tirzepatide formulations include B12? Vitamin B12 is added based on the theory that GLP-1 medications may reduce B12 absorption over time, similar to metformin. It's also thought to support energy levels during weight loss. Evidence is observational, not from randomized trials.

Is benzyl alcohol in tirzepatide safe? Yes, for the vast majority of patients. Benzyl alcohol at 0.9% concentration is a standard preservative in multi-dose vials and has been used safely in thousands of medications. Allergy or sensitivity occurs in fewer than 1 in 5,000 patients.

Can you be allergic to tirzepatide? Yes, though it's rare. Allergic reactions including anaphylaxis have been reported in post-marketing surveillance at a rate of fewer than 1 in 10,000 patients. Symptoms include hives, swelling, difficulty breathing, and rapid heart rate.

What should I do if I have a reaction to tirzepatide? For mild injection site reactions (redness, mild swelling), rotate sites and monitor. For hives or swelling beyond the injection site, stop the medication and contact your provider same day. For difficulty breathing or throat swelling, call 911 immediately.

How long does tirzepatide stay stable after mixing? Brand-name tirzepatide is pre-mixed and stable for 24 months refrigerated, or 21 days at room temperature after first use. Compounded tirzepatide in bacteriostatic water is stable for 28 days after first puncture when refrigerated. Preservative-free compounded versions must be used within 6 to 12 hours.

Does tirzepatide contain preservatives? Brand-name Mounjaro and Zepbound are preservative-free. Compounded tirzepatide typically contains 0.9% benzyl alcohol as a preservative, which allows multi-dose vials to remain sterile for 28 days.

What is the molecular weight of tirzepatide? Tirzepatide has a molecular weight of 4,813 daltons. The molecular formula is C₂₂₅H₃₄₈N₄₈O₆₈.

Is tirzepatide FDA-approved? Brand-name tirzepatide (Mounjaro, Zepbound) is FDA-approved. Compounded tirzepatide is not FDA-approved. Compounded medications are prepared by state-licensed pharmacies in response to individual prescriptions and have not undergone the same FDA review process as brand-name drugs.

Sources

1. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
4. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obesity and Metabolism. 2020.
5. Urva S et al. A single dose of tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates comparable pharmacokinetics in Japanese and Caucasian healthy participants. Clinical Pharmacokinetics. 2022.
6. Aroda VR et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2016.
7. Pooyandjoo M et al. The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials. Obesity Reviews. 2016.
8. Patel D et al. Stability of compounded semaglutide in bacteriostatic water for injection. International Journal of Pharmaceutical Compounding. 2023.
9. Mounjaro (tirzepatide) Prescribing Information. Eli Lilly and Company. 2022.
10. Zepbound (tirzepatide) Prescribing Information. Eli Lilly and Company. 2023.
11. United States Pharmacopeia. General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2023.
12. Thomas MK et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2021.
13. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018.
14. Wilson JM et al. The novel dual GIP and GLP-1 receptor agonist tirzepatide improves cardiovascular risk markers in patients with type 2 diabetes. Diabetes Care. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, Victoza, and Saxenda are registered trademarks of Novo Nordisk. Trulicity is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.